clinical trial · NCT05975073
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen·phase2·completed·n = 53
MTAP-null Non-Small-Cell Lung CancerMTAP-null Solid TumorsAnvumetostatIDE397
brief summary
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of Anvumetostat in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of anvumetostat in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).
started
Aug 1, 2023
primary completion
Feb 25, 2026
completion
Mar 26, 2026
last updated
Apr 22, 2026
official title
A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol